The burden of disease of retinal vein occlusion: review of the literature

M Laouri; E Chen; M Looman; M Gallagher

doi:10.1038/eye.2011.92

journal article May 06, 2011

The burden of disease of retinal vein occlusion: review of the literature

M Laouri E Chen M Looman M Gallagher

Eye Vol. 25 No. 8 pp. 981-988 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/eye.2011.92

Topics

No keywords indexed for this article. Browse by subject →

References

39

[1]

Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117 (6): 1094–1101. 10.1016/j.ophtha.2010.01.058

[2]

The Royal College of Ophthalmologists. Interim guidelines for management of retinal vein occlusion. 2009. Available at: http://www.rcophth.ac.uk . Accessed June 2010.

[3]

McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010; 117 (6): 1113–1123. 10.1016/j.ophtha.2010.01.060

[4]

Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117 (2): 313–319. 10.1016/j.ophtha.2009.07.017

[5]

Mitchell P, Smith W, Chang A . Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996; 114 (10): 1243–1247. 10.1001/archopht.1996.01100140443012

[6]

Liu W, Xu L, Jonas JB . Vein occlusion in Chinese subjects. Ophthalmology 2007; 114 (9): 1795–1796. 10.1016/j.ophtha.2007.03.010

[7]

Prevalence and Systemic Risk Factors for Retinal Vein Occlusion in a General Japanese Population: The Hisayama Study

Miho Yasuda, Yutaka Kiyohara, Satoshi Arakawa et al.

Investigative Opthalmology & Visual Science 2010 10.1167/iovs.09-4453

[8]

Prevalence and risk factors of retinal vein occlusion in an Asian population

L L Lim, N Cheung, J J Wang et al.

British Journal of Ophthalmology 2008 10.1136/bjo.2008.140640

[9]

Klein R, Klein BE, Moss SE, Meuer SM . The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133–141.

[10]

Traditional and Novel Cardiovascular Risk Factors for Retinal Vein Occlusion: The Multiethnic Study of Atherosclerosis

Ning Cheung, Ronald Klein, JIE JIN WANG et al.

Investigative Opthalmology & Visual Science 2008 10.1167/iovs.08-1826

[11]

Cardiovascular Risk Factors for Retinal Vein Occlusion and Arteriolar EmboliThe Atherosclerosis Risk in Communities & Cardiovascular Health studies

T WONG, E LARSEN, R Klein et al.

Ophthalmology 2005 10.1016/j.ophtha.2004.10.039

[12]

Cugati S, Wang JJ, Rochtchina E, Mitchell P . Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006; 124 (5): 726–732. 10.1001/archopht.124.5.726

[13]

Prevalence and Systemic Risk Factors for Retinal Vein Occlusion in a General Japanese Population: The Hisayama Study

Miho Yasuda, Yutaka Kiyohara, Satoshi Arakawa et al.

Investigative Opthalmology & Visual Science 10.1167/iovs.09-4453

[14]

Klein R, Moss SE, Meuer SM, Klein BE . The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol 2008; 126 (4): 513–518. 10.1001/archopht.126.4.513

[15]

Ho JD, Tsai CY, Liou SW, Tsai RJ, Lin HC . Seasonal variations in the occurrence of retinal vein occlusion: a five-year nationwide population-based study from Taiwan. Am J Ophthalmol 2008; 145 (4): 722–728. 10.1016/j.ajo.2007.12.017

[16]

Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S . Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003; 121 (9): 1297–1302. 10.1001/archopht.121.9.1297

[17]

Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S . Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol 2010; 94 (3): 319–323. 10.1136/bjo.2007.135913

[18]

Chang MA, Fine HF, Bass E, Bressler SB, Schachat AP, Solomon SD et al. Patients’ preferences in choosing therapy for retinal vein occlusions. Retina 2007; 27 (6): 789–797. 10.1097/iae.0b013e31802c0a34

[19]

Rentz AM, Kowalski J, Revicki D, Loewenstein A, Blumenkranz MS, Yoon Y et al. Normative comparison of generic- and vision-targeted health-related quality of life (HRQL) outcomes in patients with vision loss due to macular edema following retinal vein occlusion. Invest Ophthalmol Vis Sci 2010; 51, E-abstract 4728.

[20]

Varma R, Bressler NM, Suner IJ, Lee P, Dolan CM, Ward J et al. Ranibizumab improves patient-reported near and distance vision activities in patients with macular edema following retinal vein occlusion. Invest Ophthalmol Vis Sci 2010; 51, E-abstract 5212.

[21]

Hornberger JC, Shewade A, Doberne JW, Kowalski J, Nguyen H . A systematic literature review of utilities associated with visual acuity in retinal diseases. Invest Ophthalmol Vis Sci 2008; 49, E-abstract 4478.

[22]

Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P . Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131 (1): 61–77. 10.1016/s0002-9394(00)00709-1

[23]

Martin SC, Butcher A, Martin N, Farmer J, Dobson PM, Bartlett WA et al. Cardiovascular risk assessment in patients with retinal vein occlusion. Br J Ophthalmol 2002; 86 (7): 774–776. 10.1136/bjo.86.7.774

[24]

Doubal FN, Hokke PE, Wardlaw JM . Retinal microvascular abnormalities and stroke: a systematic review. J Neurol Neurosurg Psychiatry 2009; 80 (2): 158–165. 10.1136/jnnp.2008.153460

[25]

Ho JD, Liou SW, Lin HC . Retinal vein occlusion and the risk of stroke development: a five-year follow-up study. Am J Ophthalmol 2009; 147 (2): 283–290. 10.1016/j.ajo.2008.08.006

[26]

Hu CC, Ho JD, Lin HC . Retinal vein occlusion and the risk of acute myocardial infarction (correction of infraction): a 3-year follow-up study. Br J Ophthalmol 2009; 93 (6): 717–720. 10.1136/bjo.2008.151605

[27]

National Health Service. 2010 Annual Evidence Update on Retinal Vein Occlusion: cardiovascular morbidity and mortality associated with retinal vein occlusion. Available at http://www.library.nhs.uk/eyes . Accessed June 2010.

[28]

Mansour AM, Walsh JB, Henkind P . Mortality and morbidity in patients with central retinal vein occlusion. Ophthalmologica 1992; 204 (4): 199–203. 10.1159/000310294

[29]

Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein R, Klein BE et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114 (3): 520–524. 10.1016/j.ophtha.2006.06.061

[30]

Tsaloumas MD, Kirwan J, Vinall H, O’Leary MB, Prior P, Kritzinger EE et al. Nine year follow-up study of morbidity and mortality in retinal vein occlusion. Eye (Lond) 2000; 14 (Part 6): 821–827. 10.1038/eye.2000.230

[31]

Christoffersen N, Gade E, Knudsen L, Juel K, Larsen M . Mortality in patients with branch retinal vein occlusion. Ophthalmology 2007; 114 (6): 1186–1189. 10.1016/j.ophtha.2007.01.031

[32]

Haller JA, Bandello F, Belfort Jr R, Blumenkranz MS, Gillies M, Heier J et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117 (6): 1134.e3–1146.e3. 10.1016/j.ophtha.2010.03.032

[33]

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 2010; 117 (6): 1124.e1–1133.e1. 10.1016/j.ophtha.2010.02.022

[34]

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema Following branch retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 2010; 117 (6): 1102.e1–1112.e1. 10.1016/j.ophtha.2010.02.021

[35]

Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127 (9): 1101–1114. 10.1001/archophthalmol.2009.234

[36]

A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Standard Care to Treat Vision Loss Associated With Macular Edema Secondary to Branch Retinal Vein Occlusion

Archives of Ophthalmology 2009 10.1001/archophthalmol.2009.233

[37]

The Royal College of Ophthalmologists. Interim guidelines for management of retinal vein occlusion. 2010. Available at http://www.rcophth.ac.uk . Accessed March 2011.

[38]

Fekrat S, Shea AM, Hammill BG, Nguyen H, Kowalski JW, Schulman KA et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin 2010; 26 (1): 223–230. 10.1185/03007990903439046

[39]

Brown GC, Brown MM, Sharma S, Busbee B, Brown H . Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiol 2002; 9 (1): 1–10. 10.1076/opep.9.1.1.1715

Cited By

233

Artificial intelligence in retinal vein occlusion: Current applications, challenges, and future directions

Sónia Torres-Costa, Sofia Machado · 2026

Survey of Ophthalmology

Metrics

233

Citations

39

References

Details

Published: May 06, 2011
Vol/Issue: 25(8)
Pages: 981-988
License: View

Authors

Cite This Article

M Laouri, E Chen, M Looman, et al. (2011). The burden of disease of retinal vein occlusion: review of the literature. Eye, 25(8), 981-988. https://doi.org/10.1038/eye.2011.92

The burden of disease of retinal vein occlusion: review of the literature

You May Also Like